# Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

Source: [nature.com](https://www.nature.com/articles/s41467-026-79579-2) · 2026-11-13 · Life
Page: https://themorning.science/story/author-correction-the-conformation-selective-pi3k-inhibitor-roginolisib-in-patie-7c26c9d36812ee87
Kind: research · Impact: low

## In brief

- Nature Communications published an author correction to its first-in-human trial paper on roginolisib.
- The paper reports on patients with advanced or metastatic cancer, including metastatic uveal melanoma.
- The correction was published online on 13 November 2026 (doi:10.1038/s41467-026-79579-2); the sources do not state what was corrected.

## Why it matters

Readers citing or relying on the roginolisib trial paper should check the corrected version, since the correction may change reported details.

## What to do

- Check the corrected article at https://www.nature.com/articles/s41467-026-79579-2 to see what changed before citing it.

## Timeline

- 2026-11-13: Author correction published in Nature Communications

## Coverage

- [Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial](https://www.nature.com/articles/s41467-026-79579-2) — nature.com, 2026-11-13

Tags: roginolisib, pi3k-delta, clinical trial, uveal melanoma, oncology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science